Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab and Low-Dose Cyclophosphamide in Advanced Melanoma
NCT01740401Phase 2Terminated
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Oct 2012
- Primary completion
- Dec 2013
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ipilimumab in Malignant Melanoma (MM), sponsored by Icahn School of Medicine at Mount Sinai. Started Oct 2012; status: terminated.
02
Drugs
ipilimumab
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT01740401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01740401.